clinical trial · NCT06707753
Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
Beijing Anlong Biopharmaceutical Co., Ltd.·phase2·active not recruiting·n = 21
Wet Age-related Macular Degeneration (wAMD)AL-001
brief summary
This Phase I/IIa study is designed to evaluate the safety, tolerability, preliminary pharmacodynamics and pharmacokinetics in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will receive a single dose of AL-001 administered via suprachoroidal space injection.
started
Sep 11, 2023
primary completion
Aug 31, 2025
completion
Aug 31, 2025
last updated
Mar 19, 2025
official title
An Open-label, Nonrandomized, Single-arm, Single Dose, Dose-escalation Phase I/IIa Study to Evaluate the Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Macular Degeneration (wAMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol